TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from HBM Holdings Ltd. ( (HK:2142) ).
HBM Holdings Ltd. announced that its subsidiary, Nona Biosciences, has entered into a license agreement with Visterra, Inc. to advance biotherapeutic treatments for immune-mediated and autoimmune diseases. This collaboration leverages Nona Biosciences’ HCAb Harbour Mice® technology, which is recognized for its reduced immunogenicity and versatility, potentially enhancing HBM Holdings’ market position in the biotechnology sector.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a biotechnology company, incorporated in the Cayman Islands, focusing on innovative technology and integrated solutions for antibody and antibody-related discovery. Its subsidiary, Nona Biosciences, specializes in generating fully human monoclonal antibodies using its proprietary Harbour Mice® technology platform, aimed at advancing next-generation biotherapeutics.
Average Trading Volume: 11,489,726
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.67B
Find detailed analytics on 2142 stock on TipRanks’ Stock Analysis page.